These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Humoral immune response against P2β from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage. Fabbro DL; Olivera V; Bizai ML; Denner S; Diez C; Marcipar I; Streiger M; Arias E; del Barco M; Mendicino D; Bottasso O Am J Trop Med Hyg; 2011 Apr; 84(4):575-80. PubMed ID: 21460013 [TBL] [Abstract][Full Text] [Related]
31. EVI antibodies in patients with Chagas' disease: relationship with anti-Trypanosoma cruzi immunoglobulins and effects of specific treatment. Brener Z; Ramirez LE; Krettli AU; Cançado JR Mem Inst Oswaldo Cruz; 1983; 78(4):437-42. PubMed ID: 6443630 [TBL] [Abstract][Full Text] [Related]
32. Origin and significance of anti-heart and anti-skeletal muscle autoantibodies in Chagas' disease. Laguens RP; Cabeza Meckert P; Chambo J Res Immunol; 1991 Feb; 142(2):160-3. PubMed ID: 1714090 [No Abstract] [Full Text] [Related]
33. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients. Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791 [TBL] [Abstract][Full Text] [Related]
34. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Cordeiro FD; Martins-Filho OA; Da Costa Rocha MO; Adad SJ; Corrêa-Oliveira R; Romanha AJ Clin Diagn Lab Immunol; 2001 Jan; 8(1):112-8. PubMed ID: 11139203 [TBL] [Abstract][Full Text] [Related]
35. Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients. Skeiky YA; Benson DR; Parsons M; Elkon KB; Reed SG J Exp Med; 1992 Jul; 176(1):201-11. PubMed ID: 1377223 [TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin M antibodies against CRA and FRA recombinant antigens of Trypanosoma cruzi in chronic chagasic patients. Vasconcelos RH; Azevedo EA; Cavalcanti MG; Silva ED; Ferreira AG; Morais CN; Gomes YM Hum Immunol; 2011 May; 72(5):402-5. PubMed ID: 21371515 [TBL] [Abstract][Full Text] [Related]
37. Experimental Chagas disease. Innate immune response in Balb/c mice previously vaccinated with Trypanosoma rangeli. I. The macrophage shows immunological memory: Reality or fiction? Basso B; Marini V Immunobiology; 2014 Apr; 219(4):275-84. PubMed ID: 24321621 [TBL] [Abstract][Full Text] [Related]
38. Anti-Trypanosoma cruzi antibody isotype profiles in patients with different clinical manifestations of Chagas' disease. Morgan J; Dias JC; Gontijo ED; Bahia-Oliveira L; Correa-Oliveira R; Colley DG; Powell MR Am J Trop Med Hyg; 1996 Oct; 55(4):355-9. PubMed ID: 8916788 [TBL] [Abstract][Full Text] [Related]
39. The beta1 adrenergic effects of antibodies against the C-terminal end of the ribosomal P2beta protein of Trypanosoma cruzi associate with a specific pattern of epitope recognition. Lopez Bergami P; Gómez KA; Levy GV; Grippo V; Baldi A; Levin MJ Clin Exp Immunol; 2005 Oct; 142(1):140-7. PubMed ID: 16178868 [TBL] [Abstract][Full Text] [Related]